Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
February 03, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics Receives Authorization in the UK to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44
December 18, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
November 05, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics Reports Third Quarter 2024 Financial Results
October 09, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
September 24, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
September 06, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
August 13, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

Entrada Therapeutics Reports Second Quarter 2024 Financial Results
June 24, 2024 07:15 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces $100 Million Registered Direct Offering

BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
June 24, 2024 06:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs,...